Formycon AG, a leading independent developer of high-quality biosimilars, announced it will publish its financial results for the fiscal year 2025 on April 22, 2026. The company's Management Board will host a conference call and webcast on the same day at 3:00 PM (CEST) to discuss the company's development, key financial figures, and provide an outlook for the 2026 fiscal year. Interested parties can register for the call at https://webcast.meetyoo.de/reg/lNibT8TVWubG, after which they will receive a confirmation email with dial-in details. The presentation and audio broadcast will be accessible via https://www.webcast-eqs.com/formycon-2025-fy. Following a brief presentation, the Management Board will field questions from analysts. The call will be recorded and later available on Formycon's website at https://www.formycon.com/en/investor-relations/publications/.
In addition to the earnings release, Formycon's management will participate in several international investor conferences during the second quarter of 2026. On May 11-12, CFO Enno Spillner will attend the Equity Forum Spring Conference in Frankfurt, Germany. On May 28, the company will publish its first quarter 2026 results, followed by a conference call and webcast with CEO Dr. Stefan Glombitza, CFO Enno Spillner, CBO Nicola Mikulcik, and CSO Dr. Andreas Seidl. In June, Spillner will represent Formycon at the Jefferies Global Healthcare Conference in New York City (June 2-4) and the UBS Life Sciences Conference in London (June 18). Additionally, the entire management team will participate in the mwb research Roundtable webcast on June 8 and the Annual General Meeting on June 10 in Munich. A full financial calendar is available at https://www.formycon.com/en/investors/financial-calendar/.
Formycon focuses on developing biosimilars—follow-on biologics that offer cost-effective alternatives to expensive biopharmaceuticals. The company currently markets two biosimilars: FYB201 (ranibizumab) and FYB202 (ustekinumab). FYB203 (aflibercept) has received approval from the FDA, EMA, and MHRA. Four pipeline candidates, including FYB208 (dupilumab), are in development. With global biosimilar sales projected to rise from approximately $21 billion to over $74 billion by 2030, Formycon's active engagement with investors underscores its strategic positioning in this growing market.
